PT  - JOURNAL ARTICLE
AU  - Ludivine Grzelak
AU  - Sarah Temmam
AU  - Cyril Planchais
AU  - Caroline Demeret
AU  - Christèle Huon
AU  - Florence Guivel-Benhassine
AU  - Isabelle Staropoli
AU  - Maxime Chazal
AU  - Jeremy Dufloo
AU  - Delphine Planas
AU  - Julian Buchrieser
AU  - Maaran Michael Rajah
AU  - Remy Robinot
AU  - Françoise Porrot
AU  - Mélanie Albert
AU  - Kuang-Yu Chen
AU  - Bernadette Crescenzo
AU  - Flora Donati
AU  - François Anna
AU  - Philippe Souque
AU  - Marion Gransagne
AU  - Jacques Bellalou
AU  - Mireille Nowakowski
AU  - Marija Backovic
AU  - Lila Bouadma
AU  - Lucie Le Fevre
AU  - Quentin Le Hingrat
AU  - Diane Descamps
AU  - Annabelle Pourbaix
AU  - Yazdan Yazdanpanah
AU  - Laura Tondeur
AU  - Camille Besombes
AU  - Marie-Noëlle Ungeheuer
AU  - Guillaume Mellon
AU  - Pascal Morel
AU  - Simon Rolland
AU  - Felix Rey
AU  - Sylvie Behillil
AU  - Vincent Enouf
AU  - Audrey Lemaitre
AU  - Marie-Aude Créach
AU  - Stephane Petres
AU  - Nicolas Escriou
AU  - Pierre Charneau
AU  - Arnaud Fontanet
AU  - Bruno Hoen
AU  - Timothée Bruel
AU  - Marc Eloit
AU  - Hugo Mouquet
AU  - Olivier Schwartz
AU  - Sylvie van der Werf
TI  - SARS-CoV-2 serological analysis of COVID-19 hospitalized patients, pauci-symptomatic individuals and blood donors
AID  - 10.1101/2020.04.21.20068858
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.21.20068858
4099  - http://medrxiv.org/content/early/2020/04/24/2020.04.21.20068858.short
4100  - http://medrxiv.org/content/early/2020/04/24/2020.04.21.20068858.full
AB  - It is of paramount importance to evaluate the prevalence of both asymptomatic and symptomatic cases of SARS-CoV-2 infection and their antibody response profile. Here, we performed a pilot study to assess the levels of anti-SARS-CoV-2 antibodies in samples taken from 491 pre-epidemic individuals, 51 patients from Hôpital Bichat (Paris), 209 pauci-symptomatic individuals in the French Oise region and 200 contemporary Oise blood donors. Two in-house ELISA assays, that recognize the full-length nucleoprotein (N) or trimeric Spike (S) ectodomain were implemented. We also developed two novel assays: the S-Flow assay, which is based on the recognition of S at the cell surface by flow-cytometry, and the LIPS assay that recognizes diverse antigens (including S1 or N C-terminal domain) by immunoprecipitation. Overall, the results obtained with the four assays were similar, with differences in sensitivity that can be attributed to the technique and the antigen in use. High antibody titers were associated with neutralisation activity, assessed using infectious SARS-CoV-2 or lentiviral-S pseudotypes. In hospitalized patients, seroconversion and neutralisation occurred on 5-14 days post symptom onset, confirming previous studies. Seropositivity was detected in 29% of pauci-symptomatic individuals within 15 days post-symptoms and 3 % of blood of healthy donors collected in the area of a cluster of COVID cases. Altogether, our assays allow for a broad evaluation of SARS-CoV2 seroprevalence and antibody profiling in different population subsets.Competing Interest StatementLG, ST, CP, CD, CH, FGB, IS, MC, JD, DP, JB, MMR, RR, FP, MA, KYC, BC, FD, FA, PS, MG, JB, MN, MB, LB, LLF, QLH, DD, AP, YY, LT, CB, MNU, GM, PM, SR, FR, SB, VE, AL, MAC, SP, NE, AF, BH, TB, ME, HM, OS and SVDW have no competing interest to declare. PC is the founder and CSO of TheraVectys.Funding StatementOS lab is funded by Institut Pasteur, ANRS, Sidaction, the Vaccine Research Institute (ANR- 10-LABX-77), Labex IBEID (ANR-10-LABX-62-IBEID), "TIMTAMDEN" ANR-14-CE14-0029, "CHIKV-Viro-Immuno" ANR-14-CE14-0015-01 and the Gilead HIV cure program. LG is supported by the French Ministry of Higher Education, Research and Innovation. ME lab is funded by Institut Pasteur, Labex IBEID (ANR-10-LABX-62-IBEID), Reacting, EU grant Recover, ANR Oh’ticks. HM received core grants from the G5 Institut Pasteur Program, the Milieu Intérieur Program (ANR-10-LABX-69-01) and INSERM. C.P. is supported by a fellowship from the Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS). SVDW lab is funded by Institut Pasteur, CNRS, Université de Paris, Santé publique France, Labex IBEID (ANR-10-LABX-62-IBEID), REACTing, EU grant RecoverAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data generated or analysed during this study are included in this published article (and its supplementary information files).